Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.675 USD | -3.34% | -9.23% | -24.64% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Press Releases